risks relating to the early stage of product candidates under development
Contract Categories:
Business Operations
- Development Agreements
EX-10.23 8 w32132exv10w23.htm EXHIBIT 10.23 exv10w23
Exhibit 10.23
Stock Option Agreement Amendment
This Stock Option Agreement Amendment is made as of this ___ 26th___ day of December, 2006 (this Amendment), between AVALON PHARMACEUTICALS, INC., a Delaware corporation (the Company) and GARY LESSING (Executive and together with the Company, the Parties).
WHEREAS, the Company has granted to Executive options to purchase shares of the Companys common stock under one or more stock option agreements attached hereto (each such option agreement being hereinafter referred to as an Option Agreement and each such option awarded thereunder to Executive being hereinafter referred to as an Option); and
WHEREAS, in consideration of Executives continued employment with the Company, the Parties want to amend the Option Agreements on the terms and conditions set forth in this Amendment.
Now, therefore, in consideration of the foregoing, the Parties agree as follows:
1. Each Option Agreement is hereby amended to provide that, contingent upon the achievement or occurrence of any Milestone (as defined below), and notwithstanding any statement to the contrary contained in any Option Agreement, following the termination of Executives employment with the Company for any reason (other than for cause, as defined in each applicable Option Agreement, as amended):
(a) All Options vested as of the date of such termination of employment (or that shall become vested on account of such termination or that shall subsequently vest in accordance with paragraph (b) below) shall remain exercisable for a period of time equal to the lesser of (i) thirty-nine (39) months following the date of such termination, and (ii) the unexpired term of such Option as set forth in the applicable Option Agreement (disregarding for purposes of this clause (ii) any provisions set forth in the applicable Option Agreement relating to the period of exercise of such Option following the termination of Executives employment with the Company); and
(b) To the extent any Option Agreement provides for vesting of Options contingent upon the achievement by the Company or Executive of any performance milestone(s) (i.e., vesting is contingent upon the achievement of certain specified corporate or individual goals rather than Executives continued employment with the Company for a specified period of time), Executive shall continue to be entitled to the vesting of such Options in accordance with the terms of such Option Agreement upon the achievement of such performance milestones, notwithstanding Executives prior termination of employment with the Company.
2. As used herein, the term Milestone means any one or more of the following: (A) the continued employment of Executive by the Company from the date hereof until the one year anniversary of the date hereof (the Completion Date), (B) the closing of an equity financing by the Company with a total offering size that exceeds $10,000,000 within nine (9)
months following the date hereof; provided Executive continues to be employed by the Company through the closing of such financing, or (C) Executives employment is terminated by the Company without Cause (as defined in Executives employment agreement, as amended) or Executive terminates his employment with the Company for Good Reason (as defined in Executives employment agreement, as amended) prior to the Completion Date.
3. To the extent any Options are incentive stock options issued to Executive in accordance with Section 422 of the Internal Revenue Code of 1986, as amended (the Code), Executive acknowledges and agrees that the foregoing amendments shall convert such Options from incentive stock options to non-qualified stock options which are not intended to meet the requirements of Section 422 of the Code. Executive expressly consents to the conversion of any Options that constitute incentive stock options to non-qualified stock options by virtue of the foregoing amendments to Executives Option Agreements.
4. Except as set forth in this Amendment, the terms and conditions of the Option Agreements shall remain in full force and effect.
[SIGNATURES ON NEXT PAGE]
IN WITNESS WHEREOF, the Parties have executed this Stock Option Agreement Amendment as of the date first set forth above.
AVALON PHARMACEUTICALS, INC. | ||||
By: | /s/ Kenneth C. Carter | |||
Name: | ||||
Title: | CEO and President | |||
EXECUTIVE: | ||||
/s/ Gary Lessing | ||||
Gary Lessing | ||||
Attachment A
Option Agreements
Grant | # | Grant | ||
Date | Shares | Price | ||
10/23/2001 | 46,875 | $3.20 | ||
05/03/2002 | 12,500 | $3.20 | ||
10/26/2005 | 27,710 | $6.00 | ||
10/26/2005 | 15,833 | $6.00 | ||
11/30/2005 | 28,713 | $5.50 | ||
11/30/2005 | 54,543 | $5.50 | ||
12/06/2006 | 86,185 | $3.80 | ||
12/06/2006 | 26,315 | $3.80 | ||
298,674 |